Merck KGaA, Darmstadt, Germany, met its targets for 2017 and achieved important strategic successes with the approvals of two new medicines. Sales increased over the previous year whereas EBITDA pre, which was adversely impacted by negative foreign exchange effects, declined slightly.   “2017 was a good year for us. We performed well in a challenging environment and met all our targets for the year,” said Stefan Oschmann, chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, German...